PortfoliosLab logoPortfoliosLab logo
NVZMY vs. SNY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NVZMY vs. SNY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Novozymes AS (NVZMY) and Sanofi (SNY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NVZMY achieves a -9.58% return, which is significantly lower than SNY's -3.34% return. Over the past 10 years, NVZMY has underperformed SNY with an annualized return of 3.09%, while SNY has yielded a comparatively higher 5.00% annualized return.


NVZMY

1D
-0.02%
1M
-8.79%
YTD
-9.58%
6M
-7.84%
1Y
-19.84%
3Y*
6.95%
5Y*
-3.39%
10Y*
3.09%

SNY

1D
4.74%
1M
2.35%
YTD
-3.34%
6M
-4.21%
1Y
-5.37%
3Y*
0.11%
5Y*
0.98%
10Y*
5.00%
*Multi-year figures are annualized to reflect compound growth (CAGR)

NVZMY vs. SNY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
NVZMY
Novozymes AS
-9.58%14.29%3.97%12.42%-38.46%46.93%18.10%10.28%-20.91%69.59%
SNY
Sanofi
-3.34%4.93%1.09%6.55%0.57%7.00%0.39%20.47%6.06%9.96%

Correlation

The correlation between NVZMY and SNY is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.34

Correlation (3Y)
Calculated over the trailing 3-year period

0.26

Correlation (5Y)
Calculated over the trailing 5-year period

0.21

Correlation (10Y)
Calculated over the trailing 10-year period

0.26

Correlation (All Time)
Calculated using the full available price history since Jul 16, 2007

0.30

The correlation between NVZMY and SNY shifts across timeframes, from 0.21 (5 years) to 0.34 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

NVZMY:

$26.50B

SNY:

$106.88B

EPS

NVZMY:

$1.28

SNY:

$3.09

PE Ratio

NVZMY:

44.43

SNY:

14.37

PS Ratio

NVZMY:

2.41

SNY:

2.29

PB Ratio

NVZMY:

2.42

SNY:

1.47

Total Revenue (TTM)

NVZMY:

$11.07B

SNY:

$47.35B

Gross Profit (TTM)

NVZMY:

$5.79B

SNY:

$34.18B

EBITDA (TTM)

NVZMY:

$3.39B

SNY:

$12.63B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NVZMY vs. SNY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVZMY
NVZMY Risk / Return Rank: 1313
Overall Rank
NVZMY Sharpe Ratio Rank: 99
Sharpe Ratio Rank
NVZMY Sortino Ratio Rank: 1010
Sortino Ratio Rank
NVZMY Omega Ratio Rank: 1111
Omega Ratio Rank
NVZMY Calmar Ratio Rank: 1717
Calmar Ratio Rank
NVZMY Martin Ratio Rank: 1616
Martin Ratio Rank

SNY
SNY Risk / Return Rank: 3030
Overall Rank
SNY Sharpe Ratio Rank: 3333
Sharpe Ratio Rank
SNY Sortino Ratio Rank: 2828
Sortino Ratio Rank
SNY Omega Ratio Rank: 2828
Omega Ratio Rank
SNY Calmar Ratio Rank: 3131
Calmar Ratio Rank
SNY Martin Ratio Rank: 3030
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NVZMY vs. SNY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Novozymes AS (NVZMY) and Sanofi (SNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


NVZMYSNYDifference
Sharpe ratioReturn per unit of total volatility

-0.60

Sortino ratioReturn per unit of downside risk

-0.98

Omega ratioGain probability vs. loss probability

0.87

0.98

-0.11

Calmar ratioReturn relative to maximum drawdown

-0.67

-0.32

-0.35

Martin ratioReturn relative to average drawdown

-1.16

-0.64

-0.53

NVZMY vs. SNY - Sharpe Ratio Comparison

The current NVZMY Sharpe Ratio is -0.82, which is lower than the SNY Sharpe Ratio of -0.21. The chart below compares the historical Sharpe Ratios of NVZMY and SNY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


NVZMYSNYDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.82

-0.21

-0.60

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.12

0.04

-0.16

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.11

0.21

-0.10

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.08

0.21

-0.29

Drawdowns

NVZMY vs. SNY - Drawdown Comparison

The maximum NVZMY drawdown since its inception was -86.29%, which is greater than SNY's maximum drawdown of -46.46%. Use the drawdown chart below to compare losses from any high point for NVZMY and SNY.


Loading charts...

Drawdown Indicators


NVZMYSNYDifference

Max Drawdown

Largest peak-to-trough decline

-86.29%

-46.46%

-39.83%

Max Drawdown (1Y)

Largest decline over 1 year

-29.64%

-16.70%

-12.94%

Max Drawdown (3Y)

Largest decline over 3 years

-29.64%

-23.37%

-6.27%

Max Drawdown (5Y)

Largest decline over 5 years

-51.86%

-33.52%

-18.34%

Max Drawdown (10Y)

Largest decline over 10 years

-51.86%

-33.52%

-18.34%

Current Drawdown

Current decline from peak

-61.08%

-17.67%

-43.41%

Average Drawdown

Average peak-to-trough decline

-57.42%

-12.19%

-45.23%

Ulcer Index

Depth and duration of drawdowns from previous peaks

17.08%

8.47%

+8.61%

Volatility

NVZMY vs. SNY - Volatility Comparison

Novozymes AS (NVZMY) and Sanofi (SNY) have volatilities of 7.10% and 7.22%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NVZMYSNYDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.10%

7.22%

-0.12%

Volatility (6M)

Calculated over the trailing 6-month period

16.74%

15.69%

+1.05%

Volatility (1Y)

Calculated over the trailing 1-year period

24.59%

25.40%

-0.81%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

27.71%

24.77%

+2.94%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

27.13%

23.46%

+3.67%

Dividends

NVZMY vs. SNY - Dividend Comparison

NVZMY's dividend yield for the trailing twelve months is around 1.79%, less than SNY's 5.46% yield.


PositionTTM20252024202320222021202020192018201720162015
NVZMY
Novozymes AS
1.79%1.51%1.03%2.68%1.68%0.69%0.91%1.03%1.10%1.64%0.95%0.60%
SNY
Sanofi
5.46%4.56%4.22%3.83%4.32%3.80%3.61%3.47%4.29%3.82%4.11%3.77%

Financials

NVZMY vs. SNY - Financials Comparison

This section allows you to compare key financial metrics between Novozymes AS and Sanofi. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20222023202420252026
1.14B
11.24B
(NVZMY) Total Revenue
(SNY) Total Revenue
Values in USD except per share items

NVZMY vs. SNY - Profitability Comparison

The chart below illustrates the profitability comparison between Novozymes AS and Sanofi over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

10.0%20.0%30.0%40.0%50.0%60.0%70.0%20222023202420252026
56.7%
72.1%
Portfolio components
NVZMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novozymes AS reported a gross profit of 644.63M and revenue of 1.14B. Therefore, the gross margin over that period was 56.7%.

SNY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sanofi reported a gross profit of 8.11B and revenue of 11.24B. Therefore, the gross margin over that period was 72.1%.

NVZMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novozymes AS reported an operating income of 272.81M and revenue of 1.14B, resulting in an operating margin of 24.0%.

SNY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sanofi reported an operating income of 2.27B and revenue of 11.24B, resulting in an operating margin of 20.2%.

NVZMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novozymes AS reported a net income of 202.37M and revenue of 1.14B, resulting in a net margin of 17.8%.

SNY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sanofi reported a net income of 1.61B and revenue of 11.24B, resulting in a net margin of 14.4%.


Frequently Asked Questions


NVZMY and SNY have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SNY has higher volatility (7.22%) compared to NVZMY (7.10%). In terms of maximum drawdown, NVZMY dropped -86.29% vs SNY's -46.46%.

SNY currently has the higher Sharpe Ratio (-0.21 vs -0.81), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NVZMY and SNY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer